Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard Hochster

Showing results (1-10 of 55) with videos related to

Pageof 6
Sort By:
Seminars in Oncology|February 7, 2003
The role of pemetrexed in the treatment of colorectal cancerHoward Hochster
Oncology (Williston Park, N.Y.)|August 16, 2021
The Unhappy Intersection of Cancer and COVID-19Howard Hochster
Journal of the National Cancer Institute|August 18, 2021
Early-Onset Colorectal Cancer: The Mystery RemainsCathy Eng, Howard Hochster
Oncology (Williston Park, N.Y.)|February 12, 2021
WANTED: An "All-Out" National Vaccination ProgramHoward Hochster, Julie Vose
The Oncologist|August 7, 2019
Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor TherapyMichael A Morse, Howard Hochster, Al Benson
Experimental Hematology & Oncology|October 10, 2015
Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicityYue Zhang, Howard Hochster, Stacey Stein, et al.
Clinical Journal of Oncology Nursing|June 24, 2004
Oxaliplatin: practical guidelines for administrationJoan Sorich, Beth Taubes, Allan Wagner, et al.
The Oncologist|May 25, 2006
Topotecan continuous infusion: CA-125 responses including patients pretreated with other schedules of topotecanFranco Muggia, Rebecca Kosloff, Leonard Liebes, et al.
JAMA Network Open|May 4, 2019
Keeping Checkpoint Inhibitors in CheckDaniel V T Catenacci, Howard Hochster, Samuel J Klempner
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancerHoward Hochster, Abraham Chachoua, James Speyer, et al.
Pageof 6

Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
Seminars in Oncology|February 7, 2003
The role of pemetrexed in the treatment of colorectal cancerHoward Hochster
Oncology (Williston Park, N.Y.)|August 16, 2021
The Unhappy Intersection of Cancer and COVID-19Howard Hochster
Journal of the National Cancer Institute|August 18, 2021
Early-Onset Colorectal Cancer: The Mystery RemainsCathy Eng, Howard Hochster
Oncology (Williston Park, N.Y.)|February 12, 2021
WANTED: An "All-Out" National Vaccination ProgramHoward Hochster, Julie Vose
The Oncologist|August 7, 2019
Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor TherapyMichael A Morse, Howard Hochster, Al Benson
Experimental Hematology & Oncology|October 10, 2015
Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicityYue Zhang, Howard Hochster, Stacey Stein, et al.
Clinical Journal of Oncology Nursing|June 24, 2004
Oxaliplatin: practical guidelines for administrationJoan Sorich, Beth Taubes, Allan Wagner, et al.
The Oncologist|May 25, 2006
Topotecan continuous infusion: CA-125 responses including patients pretreated with other schedules of topotecanFranco Muggia, Rebecca Kosloff, Leonard Liebes, et al.
JAMA Network Open|May 4, 2019
Keeping Checkpoint Inhibitors in CheckDaniel V T Catenacci, Howard Hochster, Samuel J Klempner
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancerHoward Hochster, Abraham Chachoua, James Speyer, et al.
Pageof 6